GlassScriptPhysician profile
Alfonso Castro
NPI 1649472069
$2,035.39
in general payments reported to CMS, 2019-2025
32 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $255 · 2021: $121 · 2022: $139 · 2023: $255 · 2024: $460 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $492.60 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $165.60 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.47 | 2019-2025 | Jascayd |
| Electromed, INC. | $95.08 | 2021-2025 | Smartvest |
| Abbvie INC. | $87.75 | 2024-2025 | |
| Vapotherm INC | $84.44 | 2022-2023 | Vapotherm |
| Astrazeneca Pharmaceuticals LP | $84.36 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $78.18 | 2019-2021 | |
| Insmed, INC. | $74.73 | 2022-2024 | Arikayce |
| Philips North America LLC | $59.06 | 2019-2020 | |
| Genzyme Corporation | $56.17 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $54.17 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $53.04 | 2019-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $50.91 | 2020-2024 | |
| Grifols USA, LLC | $47.77 | 2021-2024 | Prolastin-C Liquid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.94 | 2022-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $43.23 | 2019 | |
| Csl Behring | $42.82 | 2019 | |
| Genentech USA, INC. | $32.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.63 | 2024 | Glassia |
| United Therapeutics Corporation | $27.05 | 2019 | |
| Shionogi INC | $23.95 | 2023 | Fetroja |
| Baxter Healthcare | $19.13 | 2023 | Hillrom - Life 2000 Ventilation System |
| Portola Pharmaceuticals, LLC | $17.84 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.88 | 2020 | |
| Resmed Corp | $16.71 | 2025 | |
| Inogen, INC. | $15.62 | 2022 | |
| Nabriva Therapeutics, Plc | $14.65 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.24 | 2021 | |
| Gilead Sciences, INC. | $13.17 | 2019 | |
| Itamar Medical INC | $11.82 | 2025 | Watchpatone |
| Merck Sharp & Dohme LLC | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.